Study of GSK2862277 in Subjects Undergoing Oesophagectomy Surgery

PHASE2TerminatedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

April 28, 2015

Primary Completion Date

June 28, 2017

Study Completion Date

June 28, 2017

Conditions
Lung Injury, Acute and Respiratory Distress Syndrome, Adult
Interventions
DRUG

GSK2862277

"It is available as 26 milligrams (mg) white to off-white, uniform lyophilized cake that will be reconstituted (using reconstitution fluid formulated with polysorbate 80 in Water for Injection) to 40 mg/vial of Lyophile for reconstitution for inhalation with duration of nebulisation as approximately 3-5 min and will be administered using Pari eFlow with s30 mesh device."

DRUG

Placebo

"It is a clear, colorless to pale yellow liquid, will be administered in volume to match active dose as solution for inhalation with duration of nebulisation as approximately 3-5 min and will be administered using Pari eFlow with s30 mesh device."

Trial Locations (6)

HU16 5JQ

GSK Investigational Site, Cottingham

BT9 7AB

GSK Investigational Site, Belfast

B15 2TH

GSK Investigational Site, Birmingham

B9 5SS

GSK Investigational Site, Birmingham

CB2 0QQ

GSK Investigational Site, Cambridge

TS4 3BU

GSK Investigational Site, Middlesbrough

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02221037 - Study of GSK2862277 in Subjects Undergoing Oesophagectomy Surgery | Biotech Hunter | Biotech Hunter